Biontech: Biontech cancels study on vaccine for bowel cancer treatment - shares lose ten percent
Only in mid-August had the company caused a stir - with another study success. At the time, the shares had gained more than 100 percent. Now investors are selling again.
Biontech has halted a Phase II trial of its mRNA cancer vaccine, Autogene Cevumeran, as a standalone treatment for high-risk colorectal cancer patients who have undergone surgery. The independent Data Safety Monitoring Board concluded that continuing the study would not change the efficacy signal, citing insufficient data to make reliable statements about the treatment's effectiveness.
Biontech's stock price plummeted up to 10% on the New York Stock Exchange following the announcement. The company's co-founder, Özlem Türeci, stated that although the result was not as hoped, it provides valuable scientific insights for future development. A separate Phase 2 trial of Autogene Cevumeran for pancreatic cancer treatment will continue as planned.
Written by urgent.news from Handelsblatt's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.
